Our top pick for
Cortexyme Inc is a biotechnology business based in the US. Cortexyme shares (CRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Cortexyme employs 37 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$63.05|
|52-week range||$26.66 - $121.98|
|50-day moving average||$89.20|
|200-day moving average||$62.30|
|Wall St. target price||$108.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.94|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-27.93%|
|1 month (2021-09-17)||-28.18%|
|3 months (2021-07-16)||17.76%|
|6 months (2021-04-16)||62.92%|
|1 year (2020-10-16)||27.45%|
|2 years (2019-10-16)||173.30%|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-28.86%|
|Return on equity TTM||-50.01%|
|Market capitalisation||$1.9 billion|
TTM: trailing 12 months
There are currently 2.6 million Cortexyme shares held short by investors – that's known as Cortexyme's "short interest". This figure is 1.5% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Cortexyme shares can be evaluated.
Cortexyme's "short interest ratio" (SIR) is the quantity of Cortexyme shares currently shorted divided by the average quantity of Cortexyme shares traded daily (recently around 228186.25218914). Cortexyme's SIR currently stands at 11.42. In other words for every 100,000 Cortexyme shares traded daily on the market, roughly 11420 shares are currently held short.
However Cortexyme's short interest can also be evaluated against the total number of Cortexyme shares, or, against the total number of tradable Cortexyme shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cortexyme's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Cortexyme shares in existence, roughly 90 shares are currently held short) or 0.1455% of the tradable shares (for every 100,000 tradable Cortexyme shares, roughly 146 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cortexyme.
Find out more about how you can short Cortexyme stock.
We're not expecting Cortexyme to pay a dividend over the next 12 months.
Over the last 12 months, Cortexyme's shares have ranged in value from as little as $26.6612 up to $121.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cortexyme's is 0.9179. This would suggest that Cortexyme's shares are less volatile than average (for this exchange).
Cortexyme, Inc. , a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.